Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 130 participants.
Also called NCT01434134
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 2
- Enrolled
- 130 participants
- Registry
-
NCT01434134
-
- Other papers using this trial's data
- Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study
- Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Norway
- Registry status
- Completed
Technical summary
Registry record NCT01434134. Randomized; quadruple masking; primary purpose prevention. Start 2011-09 (registry gives no type); primary completion 2014-09 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy
- Acronym
- PRADA
- Condition
- Breast Cancer
- Condition
- Heart Failure
- Intervention (Drug)
- Metoprolol
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Candesartan
- Intervention (Drug)
- Placebo
- Lead sponsor
- University Hospital, Akershus
- Collaborator
- University of Oslo
- Collaborator
- Norwegian Cancer Society
- Collaborator
- AstraZeneca
Record details
- Record id
cardio:ct-nct01434134- Content hash
1f2a879ef76f0c48c416a05bebd304e1996566555bb4291d1b035a04b484f917